533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
36639The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221112742. doi: 10.1177/15330338221112742.
The NOD-like receptor (NLR) family, caspase recruitment (CARD) domain containing 5 (NLRC5) was dysregulated in endometrial cancer (EC). However, the potential regulatory mechanisms of NLRC5 in EC remained unclear. We aimed to explore whether NLRC5 could regulate the programmed cell death protein ligand 1 (PD-L1) in EC. We also investigated the related molecular which led to the inactivation of NLRC5 in EC. The expressions of NLRC5 and PD-L1 in endometrium tissue microarray were detected by immunohistochemistry. Pearson's correlation analysis was performed to detect the expression correlation between NLRC5 and PD-L1. Immunofluorescence staining, western blotting, and quantitative real-time PCR (qRT-PCR) were used to detect the role of NLRC5 in PD-L1 in EC cell lines. The somatic mutation in EC patients was detected by whole-exome sequencing (WGS). NLRC5 was downregulated in the endometrium of EC patients when compared to those in the normal endometrium. The level of PD-L1 in the endometrium of EC patients was higher when compared to those in the normal endometrium. There was a negative expression correlation between NLRC5 and PD-L1. NLRC5 could promote the expression of PD-L1 in EC cell lines. The mutations of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may lead to the downregulation of NLRC5 in EC patients. NLRC5 could inhibit the activation of PD-L1 in EC. Mutations of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may lead to the downregulation of NLRC5 in EC patients. Future study should investigate the mechanism of NLRC5 in PD-L1, as well as the mechanism of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK in NLRC5.
核苷酸结合寡聚化结构域样受体(NLR)家族、包含半胱天冬酶募集结构域(CARD)的 5 型(NLRC5)在子宫内膜癌(EC)中失调。然而,NLRC5 在 EC 中的潜在调节机制仍不清楚。我们旨在探讨 NLRC5 是否可以调节 EC 中的程序性细胞死亡蛋白配体 1(PD-L1)。我们还研究了导致 EC 中 NLRC5 失活的相关分子。通过免疫组织化学检测子宫内膜组织微阵列中 NLRC5 和 PD-L1 的表达。采用 Pearson 相关性分析检测 NLRC5 与 PD-L1 表达的相关性。免疫荧光染色、Western blot 和实时定量 PCR(qRT-PCR)用于检测 NLRC5 在 EC 细胞系中对 PD-L1 的作用。通过全外显子组测序(WGS)检测 EC 患者的体细胞突变。与正常子宫内膜相比,EC 患者的子宫内膜中 NLRC5 下调。与正常子宫内膜相比,EC 患者的子宫内膜中 PD-L1 水平较高。NLRC5 与 PD-L1 呈负表达相关性。NLRC5 可促进 EC 细胞系中 PD-L1 的表达。ANKRD20A2、C2orf42、ADGRB3、AVPR2、GOLGA6C 和 IPPK 的突变可能导致 EC 患者 NLRC5 的下调。NLRC5 可抑制 EC 中 PD-L1 的激活。ANKRD20A2、C2orf42、ADGRB3、AVPR2、GOLGA6C 和 IPPK 的突变可能导致 EC 患者 NLRC5 的下调。未来的研究应探讨 NLRC5 在 PD-L1 中的作用机制,以及 ANKRD20A2、C2orf42、ADGRB3、AVPR2、GOLGA6C 和 IPPK 在 NLRC5 中的作用机制。
Technol Cancer Res Treat. 2022
Cell Oncol (Dordr). 2021-6
Vaccines (Basel). 2020-11-24
Cell Death Dis. 2020-11-6
Cancer Immunol Res. 2020-10